Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

BACKGROUND: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed control, including joint health maintenance. OBJECTIVES: To assess long-term eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Konkle, Barbara A., Oldenburg, Johannes, Pasi, John, Kulkarni, Roshni, Nolan, Beatrice, Mahlangu, Johnny, Young, Guy, Brown, Simon A., Pabinger, Ingrid, Shapiro, Amy, Négrier, Claude, Blanchette, Victor, Ragni, Margaret V., Dumont, Jennifer, Lethagen, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518483/
https://www.ncbi.nlm.nih.gov/pubmed/37753224
http://dx.doi.org/10.1016/j.rpth.2023.102180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518483/
https://www.ncbi.nlm.nih.gov/pubmed/37753224
http://dx.doi.org/10.1016/j.rpth.2023.102180

Ejemplares similares